Global Therapeutic Apheresis Market Size Likely to Grow at a CAGR of 7.9% By 2035

The size of the therapeutic apheresis market in the world is estimated at USD 3.84 billion in 2025 and is expected to grow to USD 4.18 billion in 2026 and reach about USD 8.94 billion in 2035 with a CAGR of 7.9% between 2026 and 2035.

Therapeutic Apheresis Market Revenue and Trends

The world market of therapeutic apheresis includes special medical equipment, systems, and consumables to selectively remove pathogenic elements of blood, such as plasma exchange (plasmapheresis), cytapheresis (leukapheresis, plateletpheresis), and other treatments of autoimmune disorders, neurological disorders, hematological diseases, kidney disorders, and transplant-associated complications. The world market of therapeutic apheresis is increasingly expanding due to increased prevalence of chronic and autoimmune diseases, increased use of target therapy in blood purification, development of automated apheresis systems, increased regenerative medicine and CAR-T therapies, and improved reimbursement policies in major healthcare systems across the world.

What are the Factors That Have a Significant Contribution to the Growth of the therapeutic apheresis market?

Increase in chronic disorders like autoimmune disorders, multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, thrombotic thrombocytopenic purpura and hematological disorders have increased the use of therapeutic apheresis as an initial or adjunctive modality in situations where pharmacotherapy fails. The increase of the prevalence of these conditions, as well as the raising of the awareness among clinicians and patients, have boosted the rates of the procedures. Advancements in technology have led to automated user-friendly systems that have better safety related systems and single-needle access, enhanced efficiency in separation of components, with reduced procedure times and complications, and it has gained more acceptance in hospitals and specialized centres. Other forces are growing signals in regenerative therapies (e.g.: stem cell and gene therapy support), the need to use plasma-derived products to support other related therapeutic treatments, good reimbursement systems in developed markets, and investments in healthcare infrastructure in the emerging markets. Market expansion is further facilitated by government efforts to encourage blood safety, organ transplantation missions, and in partnership with the private.

Segment Insight

By Product Type

The largest share of the therapeutic apheresis market was occupied by products in 2025, which is caused by the need to use modern centrifugation and membrane filtration systems to cleanse pathological substances in a precise and automated manner. The systems are essential to treatment of therapeutic plasma exchange and cytapheresis in hospitals and dialysis facilities and are subject to high growth due to the advanced innovations in portable, high-throughput machines and integrated monitoring towards improved patient outcomes and operational efficiency.

By Distribution Channel

The direct sales with manufacturers and specialized distributors have the largest market share and it is the most important channel of making hospital procurements, long-term service contracts, consumable supplies, and technical training. The channels provide regulatory compliance services, tailored installation, maintenance, and customized clinical integration in high-volume centers handling high-complicated patient care in nephrology, neurology, hematology, and transplant units and therefore, they are preferred by institutional buyers in a regulated healthcare setting.

Regional Insights

The market of therapeutic apheresis is the most developed market in the world because North America has a high number of autoimmune and chronic diseases, well-developed healthcare systems, the prevalence of specialized centers, good reimbursement policies and presence of major device manufacturers. It is an area with strong clinical research, adaptability of novel technologies, and guideline backing on apheresis in various indications.

In the meantime, the Asia Pacific market demonstrates the highest rate of development of the therapeutic apheresis market, as there is an increase in healthcare spending, the weight of chronic diseases, the number of hospital chains, the medical tourism that develops to obtain high-tech treatment methods and the modernization of blood purification services on the part of the government. The increased adoption is accelerating in countries such as China, India and Japan with investments in dialysis and apheresis infrastructure, domestic manufacturing alliances and growth in awareness of therapeutics in autoimmune and renal care.

Report Scope

Recent Developments

• In November 2025: Terumo Corporation, in partnership with Santersus AG, to develop new apheresis technology to improve the results of critically ill sepsis patients by using better blood purification.

List of the prominent players in the Therapeutic Apheresis Market:

• Terumo BCT Inc.

• Fresenius Kabi AG

• Haemonetics Corporation

• B. Braun Melsungen AG

• Asahi Kasei Medical Co. Ltd.

• Miltenyi Biotec GmbH

• Nikkiso Co. Ltd.

• Kaneka Corporation

• Mallinckrodt Pharmaceuticals (Uvadex/ECP)

• Photomedex Inc.

• Macopharma SAS

• Others

The Therapeutic Apheresis Market is segmented as follows:

By Product Type

• Apheresis Devices (Centrifugation-Based Systems, Membrane-Based Systems, Photopheresis Systems, Selective Adsorption Platforms)

• Disposables & Consumables (Apheresis Sets, Tubing Kits, Plasma Filters, Adsorption Columns, ECP Kits)

• Replacement Fluids (Albumin Solutions, Fresh Frozen Plasma, Saline)

• Other Product Types (Anticoagulants, 8-MOP Uvadex, Software Platforms, UV Irradiation Lamps)

By Procedure Type

• Therapeutic Plasma Exchange (Conventional TPE, Membrane TPE)

• Cytapheresis (Leukocytapheresis, Erythrocytapheresis, Thrombocytapheresis, Stem Cell Collection)

• LDL Apheresis (Dextran Sulfate Cellulose, HELP, Direct Adsorption)

• Immunoadsorption (Protein A, Anti-IgG, Antigen-Specific Columns)

• Extracorporeal Photopheresis (ECP)

• Rheopheresis

• Other Procedure Types (Cascade Filtration, Cryofiltration, Thermofiltration)

By Indication

• Neurological Disorders (GBS, NMOSD, Myasthenia Gravis, Anti-NMDAR Encephalitis, CIDP, MS)

• Hematological Disorders (TTP, HUS, Sickle Cell Disease, Hyperviscosity Syndrome, Polycythemia Vera, GvHD, CTCL)

• Renal Disorders (ANCA-Vasculitis, Anti-GBM Disease, FSGS, Transplant Rejection)

• Cardiovascular Disorders (Familial Hypercholesterolemia, High Lp(a), Dilated Cardiomyopathy)

• Autoimmune Disorders (SLE, RA, Pemphigus, Systemic Sclerosis, ANCA Vasculitis)

• Other Indications (Drug Intoxication, Hypertriglyceridemia-Induced Pancreatitis, Cytokine Storm)

By End-User

• Hospitals & Academic Medical Centers (Level I Trauma Centers, University Hospitals)

• Dialysis Centers (Nephrology Units with Apheresis Capability)

• Specialty Treatment Centers (Dedicated Apheresis Units, Neurology Centers, Transplant Centers)

• Other End-Users (Oncology Centers, Military Healthcare, Research Institutes)

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America